Mothers against decapentaplegic homolog 4 (SMAD4)

Mothers against decapentaplegic homolog 4 (SMAD4) is a key intracellular signal transducer and transcription factor within the transforming growth factor beta (TGF-β) signaling pathway. It acts as a common mediator (co-SMAD), forming complexes with receptor-regulated SMADs (R-SMADs) after their activation by TGF-β family ligands. These complexes translocate to the nucleus to regulate the transcription of target genes, with broad functions in cell proliferation, apoptosis, differentiation, embryonic development, and tumor suppression. SMAD4 is critically involved in normal tissue homeostasis, and loss-of-function mutations lead to hereditary polyposis syndromes and contribute to the pathogenesis of various cancers, especially pancreatic and colorectal cancers. Gain-of-function mutations are found in rare disorders such as Myhre syndrome. The protein is not directly druggable with clinically approved agents, but its function and status are important as a biomarker and in the pharmacological targeting of pathways in oncology and fibrosis[1][2][3][4].

Other names

SMAD4DPC4MADH4Co-SMADCommon mediator SMAD

Inhibitors of the TGF-β pathway block SMAD4-mediated gene regulation; Molecules affecting SMAD4 phosphorylation, stability, or nuclear localization.